Losartan Potassium Tablet, Film Coated
Product Images NDC 87441-052

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 87441-052). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan 25 mg (8744105201 Losartan Potassium 25 mg)

Losartan Potassium Tablets, USP 25 mg film-coated oral tablets label. The label is for a prescription drug repackaged by Unit Dose Solutions, Inc. and distributed by Tuckhoe Enterprises, LLC. It includes dosage strength, storage instructions, dispensing directions for pharmacists, and addresses for repackager and distributor.*

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

Chemical structure of Losartan Potassium, showing the molecular arrangement including chlorine, hydroxyl, and potassium ion components.*

FDA Label Image

Figure 1 (Spl Image2 Figure1)

A line graph comparing the percentage of patients with the primary endpoint over study months for Atenolol and Losartan Potassium. The x-axis represents study months from 0 to 66, and the y-axis shows the percentage of patients from 0 to 16%. Losartan Potassium shows a lower percentage of patients reaching the primary endpoint compared to Atenolol, with an adjusted risk reduction of 13% (p=0.021).*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

A line graph comparing the percentage of patients experiencing fatal or non-fatal stroke over 66 months between Atenolol and Losartan Potassium. The x-axis represents study months from 0 to 66, and the y-axis shows the percentage of affected patients from 0 to 8%. Losartan Potassium shows a lower stroke incidence compared to Atenolol, with a noted adjusted risk reduction of 25% (p=0.001).*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

A forest plot chart titled 'Primary Endpoint Events within Demographic Subgroups' comparing event rates and hazard ratios between Losartan Potassium and Atenolol for Primary Composite and Stroke (Fatal/Non-fatal) outcomes across various demographic categories such as age, gender, race, ISH, diabetes, and history of cardiovascular disease. The chart includes sample sizes and proportional symbols, with a scale indicating which treatment is favored.*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

A line graph comparing the percentage of patients with an event over 48 months between Losartan Potassium and placebo groups. The x-axis represents time in months, and the y-axis indicates the percentage of patients with the event. The graph shows a 16.1% risk reduction with Losartan Potassium versus placebo, with a significant p-value of 0.022.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.